Discover the top 23 companies transforming the CAR T-cell therapy market, including Johnson & Johnson, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and other industry leaders. Backed by a market projected to grow from $6.78B to $13.56B by 2031 at a CAGR of 14.9%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top CAR T-cell Therapy Companies

Johnson & Johnson

Johnson & Johnson is a global healthcare leader that has established a significant presence in the CAR T-cell therapy market through its Innovative Medicine division. The company’s flagship cell therapy, Carvykti (ciltacabtagene autoleucel), is a BCMA-directed treatment that has demonstrated exceptional clinical results and rapid market uptake for relapsed or refractory multiple myeloma. Leveraging its extensive global R&D and manufacturing network, Johnson & Johnson is actively expanding its pipeline to include next-generation dual-targeting therapies and is exploring applications in other B-cell malignancies and solid tumors.

Gilead Sciences, Inc.

Gilead Sciences, primarily through its subsidiary Kite Pharma, is a dominant force in the CAR T-cell therapy sector, maintaining a singular focus on cell-based cures. The company boasts a leading portfolio including Yescarta and Tecartus, which address various lymphomas and leukemias. Gilead continues to strengthen its market position through strategic acquisitions, such as its recent moves to acquire Arcellx and Interius BioTherapeutics, aimed at advancing both autologous and in vivo cell therapy platforms to improve patient access and clinical outcomes.

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a premier biopharmaceutical company with a robust cell therapy franchise featuring two approved CAR-T products, Abecma and Breyanzi. The company has secured broad approvals for these therapies across multiple indications, including large B-cell lymphoma and multiple myeloma. BMS is committed to long-term growth in the sector by investing in “in vivo” CAR-T capabilities and expanding its manufacturing capacity to meet the increasing global demand for personalized cancer treatments.

Novartis AG

Novartis AG is a pioneer in the cell therapy field, having launched Kymriah, the first FDA-approved CAR T-cell therapy. While facing increased competition, the company maintains a strong global footprint and continues to innovate through its T-Charge platform, designed to preserve T-cell stemness and enhance therapy efficacy. Novartis remains a key player in the market, focusing on optimizing manufacturing processes and exploring new therapeutic targets to address unmet needs in both hematological and solid tumor oncology.

Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies. Its lead candidate, obe-cel (AUTO1), is being investigated for adult acute lymphoblastic leukemia with a focus on improved safety and persistence. The company has recently entered into a strategic partnership with BioNTech to leverage combined expertise and infrastructure, aiming to accelerate the commercialization of its autologous CAR-T programs and expand its reach within the oncology market.

JW (Cayman) Therapeutics Co., Ltd.

JW Therapeutics is a leading cell therapy company in China, focused on developing and commercializing transformative cell-based immunotherapies for the domestic market. Its primary product, Relmacabtagene autoleucel (Relma-cel), targets CD19 and is approved for several B-cell malignancies in China. The company leverages international collaborations and localized manufacturing expertise to provide high-quality, innovative cell therapies to a large and growing patient population in the Asia-Pacific region.

Immunoadoptive Cell Therapy Private Limited (ImmunoACT)

ImmunoACT is an emerging Indian health-tech company that has successfully developed NexCAR19, India’s first indigenous CAR T-cell therapy. By focusing on cost-effective manufacturing and localized delivery, the company aims to democratize access to advanced cell therapies for patients with B-cell lymphomas and leukemias. ImmunoACT’s successful clinical trials and recent commercial launch represent a significant milestone in making high-end personalized medicine affordable in developing markets.

CarSgen Therapeutics Holdings Limited

CarSgen Therapeutics is a global clinical-stage biopharmaceutical company specializing in CAR-T cell therapies for both hematological malignancies and solid tumors. The company employs advanced technology platforms, such as its CycloCAR and THANK-homing designs, to enhance the efficacy of its pipeline, which includes candidates targeting Claudin 18.2 and GPC3. CarSgen’s strategic focus on overcoming the challenges of treating solid tumors positions it as a highly innovative player in the evolving cell therapy landscape.

Iaso Biotherapeutics

Iaso Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel cell therapies and biologics for oncology and autoimmune diseases. Its lead product, Fiasel (equecabtagene autoleucel), is a BCMA-directed CAR-T therapy developed in collaboration with Innovent Biologics. Iaso continues to expand its pipeline with multi-specific CAR-Ts and off-the-shelf products, utilizing its fully integrated platform to drive innovation from discovery through to commercialization.

Immuneel Therapeutics

Immuneel Therapeutics is an Indian biotechnology company focused on bringing affordable, high-quality cell therapies to India and other emerging markets. In 2025, the company launched Qartemi (varnimcabtagene autoleucel), a CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma. By establishing state-of-the-art manufacturing facilities and partnering with leading global institutions, Immuneel is playing a critical role in increasing the accessibility of curative cancer treatments in the Asia-Pacific region.

Wugen

Wugen is a clinical-stage biotechnology company developing “off-the-shelf” allogeneic cell therapies for memory T cells and NK cells to treat both hematological and solid tumors. The company’s focus on allogeneic platforms aims to overcome the scalability and timing limitations of traditional autologous CAR-T treatments. Wugen’s innovative approach to utilizing memory T cells is designed to provide more persistent and effective immune responses against difficult-to-treat cancers.

Cartesian Therapeutics, Inc.

Cartesian Therapeutics is a clinical-stage biopharmaceutical company pioneering the use of mRNA-engineered cell therapies for autoimmune diseases and oncology. Its lead candidate, Descartes-08, is a first-in-class mRNA CAR-T therapy being evaluated for myasthenia gravis and other autoimmune conditions. Unlike traditional DNA-based CAR-Ts, Cartesian’s mRNA approach allows for predictable, transient expression, potentially offering a safer profile for chronic conditions outside of late-stage cancer.

Allogene Therapeutics

Allogene Therapeutics is a leader in the development of allogeneic (off-the-shelf) CAR T-cell therapies, aiming to provide faster and more scalable treatment options compared to patient-specific therapies. The company’s pipeline includes several clinical-stage candidates targeting CD19 and BCMA, utilizing advanced gene-editing technologies to prevent graft-versus-host disease. Allogene’s strategy focuses on delivering high-quality cell therapies at a lower cost and with reduced wait times for patients with various blood cancers.

Lyell Immunopharma, Inc.

Lyell Immunopharma is a clinical-stage T-cell reprogramming company dedicated to overcoming the primary barriers to successful T-cell therapy: exhaustion and lack of durable stemness. The company applies proprietary technologies, such as its Gen-R and Epi-R platforms, to enhance the function and fitness of T cells. Lyell’s research is focused on developing next-generation therapies for solid tumors, aiming to create more robust and long-lasting clinical responses through fundamental improvements in T-cell biology.

Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage cell therapy company focused on utilizing CAR T-cells to treat serious autoimmune diseases. Its lead program, KYV-101, is a CD19-directed autologous CAR-T therapy designed to deplete B cells and reset the immune system in patients with refractory autoimmune conditions like lupus nephritis and multiple sclerosis. Kyverna is at the forefront of expanding the application of CAR-T technology beyond oncology into the vast field of immunology.

Cellectis SA

Cellectis SA is a clinical-stage biotechnology company and a pioneer in the field of gene editing, specializing in the development of allogeneic CAR T-cell therapies. Using its proprietary TALEN technology, the company creates universal “off-the-shelf” cell products designed to be compatible with any patient. Cellectis maintains a diverse pipeline and collaborates with major pharmaceutical partners, positioning its gene-editing expertise as a foundational element in the next generation of adoptive immunotherapy.

Brainchild Bio

Brainchild Bio is a specialized biotechnology company focused on developing CAR T-cell therapies specifically for central nervous system (CNS) tumors, including pediatric and adult brain cancers. The company utilizes novel delivery methods and multi-antigen targeting strategies to penetrate the blood-brain barrier and address the high heterogeneity of glioblastomas. Brainchild Bio’s mission is to bring the curative potential of cell therapy to some of the most challenging and underserved areas of oncology.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop treatments for cancers and autoimmune diseases. The company’s most advanced program, Tabelecleucel, is approved in Europe for EBV-associated post-transplant lymphoproliferative disease. Atara is also advancing CAR-T programs for solid tumors, utilizing its off-the-shelf technology to provide rapid access to therapies that harness the natural power of the immune system.

Caribou Biosciences

Caribou Biosciences is a clinical-stage CRISPR genome-editing company founded by Nobel laureate Jennifer Doudna. The company is developing a pipeline of “off-the-shelf” CAR-T and CAR-NK cell therapies using its proprietary chRDNA technology for high-precision editing. Caribou’s lead candidate, CB-010, has received RMAT and Fast Track designations from the FDA, reflecting the potential of its edited allogeneic therapies to improve durability and outcomes for patients with B-cell non-Hodgkin lymphoma.

Arcellx

Arcellx is a clinical-stage biotechnology company focused on reimagining cell therapy through its innovative D-Domain technology, which aims to improve the specificity and binding affinity of CAR-T cells. Its lead candidate, anito-cel (anitocabtagene autoleucel), is being co-developed with Kite Pharma for multiple myeloma and has shown deep and durable clinical responses. Arcellx’s versatile platform is designed to overcome the limitations of traditional binders, paving the way for safer and more effective treatments across oncology and immunology.

CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company that utilizes the CRISPR/Cas9 platform to develop transformative medicines, including allogeneic CAR T-cell therapies. The company’s immuno-oncology pipeline features candidates like CTX110 and CTX130, which are engineered to target various cancers while minimizing the risk of graft-versus-host disease. CRISPR Therapeutics continues to advance its technology to create more potent and persistent “off-the-shelf” cell products for a broad range of hematological and solid tumors.

Poseida Therapeutics

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platforms, including piggyBac and Cas-CLOVER, to create high-quality cell and gene therapies. The company’s CAR-T programs focus on producing therapies with a high percentage of stem cell memory T cells, which are associated with better persistence and anti-tumor activity. Poseida is currently collaborating with Roche to develop allogeneic CAR-T therapies for multiple myeloma and other hematological cancers, emphasizing safety and scalability.

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company dedicated to discovering and developing targeted T-cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary CABA platform allows for the engineering of Chimeric Antigen Receptor T cells for Autoimmunity (CARTA), such as its lead candidate CABA-201. By specifically depleting B cells, Cabaletta Bio aims to provide deep and durable remissions for patients suffering from refractory autoimmune conditions, potentially offering a “one-and-done” treatment approach.

Download PDF Brochure:“Click Here”